Tao Wang

Dr. Tao Wang


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2008 in Expert Review of Anticancer Therapy
Verified
Journal Article
Closed access
TFTJ FitzGerald
TJ FitzGerald
TWTao Wang
Tao Wang
HGHira Lal Goel
Hira Lal Goel
JHJiayi Huang
Jiayi Huang
GSGary Stein
Gary Stein
Lucia LanguinoLucia Languino
Lucia Languino
(2008). Prostate carcinoma and radiation therapy: therapeutic treatment resistance and strategies for targeted therapeutic intervention. Expert Review of Anticancer Therapy: Vol. 8, No. 6, pp. 967-974.

1 October 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AKAyush Kumar
Ayush Kumar
HGHira Lal Goel
Hira Lal Goel
CWChristi A Wisniewski
Christi A Wisniewski
TWTao Wang
Tao Wang
YGYansong Geng
Yansong Geng
AMArthur M. Mercurio
Arthur M. Mercurio
The high rate of recurrence after radiation therapy in triple-negative breast cancer (TNBC) indicates that novel approaches and targets are needed to enhance radiosensitivity. Here, we report that neuropilin-2 ( NRP2 ), a receptor for vascular endothelial growth factor ( VEGF ) that is enriched on subpopulations of TNBC cells with stem cell properties, is an effective therapeutic target for sensitizing TNBC to radiotherapy. Specifically, VEGF/NRP2 signaling induces nitric oxide synthase 2 ( NOS2 ) transcription by a mechanism dependent on Gli1. NRP2-expressing tumor cells serve as a hub to produce nitric oxide (NO), an autocrine and paracrine signaling metabolite, which promotes cysteine-nitrosylation of Kelch-like ECH-associated protein 1 ( KEAP1 ) and, consequently, nuclear factor erythroid 2-related factor 2–mediated ( NFE2L2 -mediated) transcription of antioxidant response genes. Inhibiting VEGF binding to NRP2, using a humanized mAb, results in NFE2L2 degradation via KEAP1, rendering cell lines and organoids vulnerable to irradiation. Importantly, treatment of patient-derived xenografts with the NRP2 mAb and radiation resulted in significant tumor necrosis and regression compared with radiation alone. Together, these findings reveal a targetable mechanism of radioresistance, and they support the use of NRP2 mAb as an effective radiosensitizer in TNBC.

1 January 2011 in Frontiers in Oncology
Verified
Journal Article
Open access
TWTao Wang
Tao Wang
Lucia LanguinoLucia Languino
Lucia Languino
JLJane Lian
Jane Lian
GSGary S Stein
Gary S Stein
MBMichael Blute
Michael Blute
TFThomas J. FitzGerald
Thomas J. FitzGerald
Recent selected developments of the molecular science of prostate cancer (PrCa) biology and radiation oncology are reviewed. We present potential targets for molecular integration treatment strategies with radiation therapy (RT), and highlight potential strategies for molecular treatment in combination with RT for patient care. We provide a synopsis of the information to date regarding molecular biology of PrCa, and potential integrated research strategy for improved treatment of PrCa. Many patients with early-stage disease at presentation can be treated effectively with androgen ablation treatment, surgery, or RT. However, a significant portion of men are diagnosed with advanced stage/high-risk disease and these patients progress despite curative therapeutic intervention. Unfortunately, management options for these patients are limited and are not always successful including treatment for hormone refractory disease. In this review, we focus on molecules of extracellular matrix component, apoptosis, androgen receptor, RUNX, and DNA methylation. Expanding our knowledge of the molecular biology of PrCa will permit the development of novel treatment strategies integrated with RT to improve patient outcome